The Project
The objective was agreed to deliver a business case and 5-year P&L, based on the commercial opportunities of the two identified products, within a three-month timeframe. Project started in April 2021.
In-scope:
- UK market analysis and development of sales and share opportunities in the relevant markets
- Market access critical needs and investments
- Entity and organisational set up with costs, plus market access and field force model recommendations
- Analysis of pricing process and recommendations
- 5-year P&L
Actions undertaken
- Market analysis completed, highlighting key trends, volumes, shares and pricing recommendations, through desk research and key stakeholder discussions
- Customer perspectives collated regarding product profile and key benefit analysis, through in-depth interviews with leading clinical experts and patient groups.
- Evidence package compiled following important dialogue with key stakeholders to support new guidelines under development
- Market access strategy developed with recommendations regarding NICE and SMC requirements plus insights into NHS structural and commissioning changes
- Pricing strategy finalised following direct contact with DHSC on NHS pricing process, with analysis and recommendations on best options for a pricing submission
- Selling strategy developed with recommendations on field force/market access model to enable local and regional awareness, approval and uptake
- Organisational structure and operational model agreed
Results
- Decision taken to set up a UK subsidiary following delivery of a positive business case with strong NPV.
- A major second product successfully licensed in from a third party based on forecasts and outline plan supplied by MoorPharm
- Early phase start-up contract with MoorPharm to support organisational build extended through to Phase 2
- First product launch scheduled for April 2022
We made the decision to start up our UK subsidiary based on MoorPharm’s market insight and compelling business case. Their practical approach and commercial focus provided a clear route to market, and their on-going support during the early implementation phase has been invaluable
Head of Europe – Global Healthcare Company